ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

最近更新时间: 2分钟之前

745.28

-10.11 (-1.34%)

  • 1天 -1.34%
  • 5天 0.90%
  • 1月 6.28%
  • 6月 -9.64%
  • 今年至今天 -4.21%
  • 1年 -19.30%
  • 5年 396.59%
前收盘价格 755.39
收盘价格 753.07
成交量 1,255,004
平均成交量 (3个月) 4,401,698
市值 668,111,536,128
市盈率 (P/E TTM) 48.62
预期市盈率 (P/E Forward) 25.06
价格/销量 (P/S) 12.80
股市价格/股市净资产 (P/B) 37.07
52周波幅
623.78 (-16%) — 939.86 (26%)
利润日期 30 Oct 2025
股息率 (DY TTM) 0.38%
营业毛利率 22.67%
营业利益率 (TTM) 42.49%
稀释每股收益 (EPS TTM) 12.27
季度收入增长率 (YOY) 45.20%
季度盈利增长率 (YOY) 23.00%
总债务/股东权益 (D/E MRQ) 243.61%
流动比率 (MRQ) 1.37
营业现金流 (OCF TTM) 9.32 B
杠杆自由现金流 (LFCF TTM) -1.82 B
资产报酬率 (ROA TTM) 16.45%
股东权益报酬率 (ROE TTM) 77.28%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看跌
Drug Manufacturers - General (全球的) 混合的 看跌
股票 Eli Lilly and Company 看跌 看跌

AIStockmoo 评分

-0.4
分析师共识 -0.5
内部交易活动 -3.0
价格波动 2.0
技术平均移动指标 -2.5
技术振荡指标 2.0
平均 -0.40

相关股票

股票 市值 DY P/E（TTM） P/B
LLY 668 B 0.38% 48.62 37.07
NVO 214 B 2.28% 13.42 9.25
NVS 245 B 3.23% 18.46 5.72
MRK 210 B 2.84% 12.97 4.22
JNJ 428 B 1.40% 18.99 5.48
ABBV 386 B 2.21% 103.97 50.46

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Growth
内部持股比例 0.16%
机构持股比例 83.96%

所有权

姓名 日期 持有股份
Lilly Endowment Inc 30 Jun 2025 96,016,978
Pnc Financial Services Group, Inc. 30 Jun 2025 51,293,980
52周波幅
623.78 (-16%) — 939.86 (26%)
目标价格波幅
700.00 (-6%) — 1,135.00 (-99%)
高 1,135.00 (Morgan Stanley, 52.29%) 购买
中 885.00 (18.75%)
低 700.00 (HSBC, -6.08%) 保留
平均值 888.33 (19.19%)
总计 5 购买, 1 保留
平均价格@调整类型 684.45
公司 日期 目标价格 调整类型 价格@调整类型
HSBC 27 Aug 2025 700.00 (-6.08%) 保留 734.17
Cantor Fitzgerald 13 Aug 2025 825.00 (10.70%) 购买 660.49
Guggenheim 13 Aug 2025 875.00 (17.41%) 购买 660.49
11 Jul 2025 942.00 (26.40%) 购买 793.01
Deutsche Bank 11 Aug 2025 900.00 (20.76%) 购买 635.22
UBS 08 Aug 2025 895.00 (20.09%) 购买 625.65
Morgan Stanley 10 Jul 2025 1,135.00 (52.29%) 购买 790.65
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
HERNANDEZ EDGARDO - 727.21 -17 -12,363
累积净数量 -17
累积净值 ($) -12,363
累积平均购买 ($) -
累积平均卖出 ($) 727.21
名称 持有人 日期 类型 数量 价格 价值 ($)
HERNANDEZ EDGARDO 职员 05 Sep 2025 处理 (-) 17 727.21 12,363
  • 3M
日期 类型 细节
12 Sep 2025 CNBC Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
11 Sep 2025 公告 Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
11 Sep 2025 CNBC Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
09 Sep 2025 公告 Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
09 Sep 2025 公告 Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health
08 Sep 2025 公告 Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
04 Sep 2025 公告 Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
03 Sep 2025 公告 Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
27 Aug 2025 公告 Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
26 Aug 2025 公告 Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
26 Aug 2025 CNBC Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
25 Aug 2025 公告 Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
24 Aug 2025 CNBC Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
22 Aug 2025 公告 Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
21 Aug 2025 CNBC FDA approves first-ever glucose monitoring system for weight loss from Signos 
20 Aug 2025 公告 Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
19 Aug 2025 CNBC Viking Therapeutics shares fall 40% on disappointing obesity pill trial data
18 Aug 2025 CNBC Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
14 Aug 2025 CNBC Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
07 Aug 2025 CNBC Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
07 Aug 2025 CNBC Eli Lilly shares drop after obesity pill shows modest late-stage trial results
07 Aug 2025 公告 Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
07 Aug 2025 公告 Lilly reports second-quarter 2025 financial results and raises guidance
05 Aug 2025 CNBC Trump says pharma tariffs could eventually reach up to 250%
31 Jul 2025 CNBC Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
31 Jul 2025 公告 Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
30 Jul 2025 公告 Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
29 Jul 2025 公告 Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
25 Jul 2025 公告 Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
25 Jul 2025 公告 Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
24 Jul 2025 公告 Lilly and Verve announce expiration of Verve tender offer
24 Jul 2025 公告 Lilly confirms date and conference call for second-quarter 2025 financial results announcement
21 Jul 2025 CNBC Weight loss drugs could be a gamechanger for women with a common hormonal disorder
09 Jul 2025 CNBC Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
09 Jul 2025 公告 FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
08 Jul 2025 CNBC Trump threatens to impose up to 200% tariff on pharmaceuticals 'very soon'
23 Jun 2025 公告 Lilly declares third-quarter 2025 dividend
22 Jun 2025 公告 Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
21 Jun 2025 公告 Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
17 Jun 2025 公告 Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
16 Jun 2025 公告 Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
显示更多
股息率 (DY TTM) 0.38%
5年平均股息收益率 1.10%
股息支付比率 43.94%
预计下次股息支付 Dec 2025
除息日 公告日期 支付日期 详情
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 现金
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 现金
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 现金
15 May 2024 06 May 2024 10 Jun 2024 1.3 现金
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 现金
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 现金
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 现金
12 May 2023 01 May 2023 09 Jun 2023 1.13 现金
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 现金
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 现金
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 现金
13 May 2022 02 May 2022 10 Jun 2022 0.98 现金
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 现金
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 现金
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 现金
13 May 2021 03 May 2021 10 Jun 2021 0.85 现金
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 现金
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 现金
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 现金
14 May 2020 04 May 2020 10 Jun 2020 0.74 现金
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 现金
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 现金
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 现金
16 May 2019 07 May 2019 10 Jun 2019 0.645 现金
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 现金
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 现金
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 现金
16 May 2018 07 May 2018 08 Jun 2018 0.5625 现金
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 现金
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 现金
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 现金
11 May 2017 01 May 2017 09 Jun 2017 0.52 现金
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 现金
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 现金
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 现金
11 May 2016 02 May 2016 10 Jun 2016 0.51 现金
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 现金
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 现金
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 现金
14 May 2015 04 May 2015 10 Jun 2015 0.5 现金
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 现金
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 现金
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 现金
13 May 2014 05 May 2014 10 Jun 2014 0.49 现金
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 现金
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 现金
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 现金
14 May 2013 03 May 2013 10 Jun 2013 0.49 现金
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 现金
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 现金
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 现金
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 现金
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 现金
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 现金
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 现金
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 现金
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 现金
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 现金
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 现金
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 现金
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 现金
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 现金
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 现金
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 现金
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 现金
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 现金
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 现金
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 现金
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 现金
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 现金
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 现金
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 现金
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 现金
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 现金
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 现金
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 现金
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 现金
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 现金
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 现金
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 现金
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 现金
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 现金
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 现金
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 现金
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 现金
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 现金
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 现金
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 现金
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 现金
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 现金
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 现金
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 现金
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 现金
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 现金
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 现金
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 现金
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 现金
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 现金
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 现金
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 现金
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 现金
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 现金
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 现金
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 现金
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 现金
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 现金
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 现金
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 现金
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 现金
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 现金
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 现金
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 现金
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 现金
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 现金
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 现金
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 现金
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 现金
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.50 1 0.20
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票